SAN DIEGO, Aug. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally
for use in the hospital setting, announced today that the company's
President and CEO Theodore Schroeder will present the corporate overview at
two upcoming investment conferences in New York City:
-- Wednesday, September 5, 2007 at 11:00am Eastern Time
(8:00am Pacific Time) during the Roth 2007 New York Conference, and
-- Thursday, September 6, 2007 at 3:30pm Eastern Time
(12:30pm Pacific Time) during the BIOCentury Newsmakers Conference.
These presentations will be simultaneously webcast and can be accessed
on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the
Investor Relations section. Replays of the webcasts will be available
approximately one hour following the live webcasts and will be archived for
30 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on
in-licensing, developing and commercializing proprietary product candidates
principally for use in the hospital setting. The company currently has two
Phase III product candidates in development, including intravenous
acetaminophen (IV acetaminophen) for the treatment of acute pain and fever,
and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the
prevention of catheter-related infections. For more information about
Cadence's pipeline, visit http://www.cadencepharm.com.
Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals,
Inc.
Contacts: William R. LaRue Anna Gralinska
SVP & Chief Financial Officer Director, Investor Relations
Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.
858-436-1400 858-436-1452
SOURCE Cadence Pharmaceuticals, Inc.
 back to top
Related links:
http://www.cadencepharm.com
CONTACT:
William R. LaRue, SVP & Chief Financial
Officer, +1-858-436-1400, or Anna Gralinska, Director, Investor
Relations, +1-858-436-1452, both of Cadence Pharmaceuticals, Inc.
|
